Can Adiponectin Levels Predict Surgical Outcomes in Cancer Patients?
"New Research Explores the Link Between Adiponectin, Oxidative Stress, and Post-Surgery Complications"
Undergoing surgery for cancer is a stressful experience, and how well a patient recovers can depend on various factors. One area of increasing interest is the role of adiponectin, a hormone produced by fat cells, in influencing surgical outcomes. Low levels of adiponectin have been linked to a higher risk of infection after surgery in cancer patients. However, it's not fully understood whether the stress of surgery itself affects adiponectin levels and how this relates to oxidative stress, a process that can damage cells.
To shed light on this, a new study has explored the connection between adiponectin levels, oxidative stress, and postoperative complications in patients undergoing major abdominal surgery for cancer. The goal was to see if pre-operative, intra-operative and post-operative levels of adiponectin in patients who underwent major abdominal surgery and there association with postoperative complications.
This article breaks down the key findings of this research, explaining how adiponectin might serve as a predictor of surgical outcomes and what this could mean for improving patient care.
Adiponectin and Surgical Outcomes
A 2010 study examined whether preoperative insulin resistance or adiponectin was associated with short- and long-term adverse outcomes in non-diabetic patients undergoing elective cardiac surgery. The supplied source material does not report the study’s results or provide outcome statistics, so it does not establish adiponectin’s predictive value in that population. Separately, a source describing laparoscopic abdominal cancer surgery says a recent study investigated preoperative adiponectin and oxidative stress in relation to recovery, but gives no findings or figures.
From Discovery to Clinical Interest
Adiponectin was discovered in 1995 as an adipocyte-derived hormone, although its clinical relevance initially remained unclear. A 2019 review highlights milestones including the discovery of adiponectin’s insulin-sensitizing properties and the elucidation of its receptors. By 2012, adiponectin had been widely studied and accepted as a biomarker in clinical studies, with functions examined in tissue-culture systems and genetically manipulated rodent models. A 2026 review snippet notes a clinical paradox: adiponectin levels often increase with age even as age-associated fat mass, insulin resistance, and cardiovascular risk increase.
What the Study Revealed: Adiponectin as a Potential Predictor
The study, published in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, enrolled twelve patients undergoing laparoscopic abdominal surgery for cancer. Researchers measured their adiponectin levels and markers of oxidative stress at several points: before surgery, at the end of surgery, and 24 and 48 hours after surgery. The patients were then divided into two groups based on whether they experienced postoperative complications (the CL+ group) or not (the CL- group).
- Patients in the CL- group (those without complications) had significantly higher preoperative adiponectin levels compared to the CL+ group.
- There was an inverse relationship between preoperative adiponectin levels and the severity of postoperative complications. In other words, the lower the adiponectin levels before surgery, the more severe the complications tended to be.
- While adiponectin levels decreased during surgery in both groups, oxidative stress tended to increase.
Perioperative Adiponectin Research
A study of patients with colorectal cancer undergoing laparoscopic surgery calculated its sample size to detect a 25% relative difference in adiponectin between groups, based on a postoperative response reported in an earlier study by Chelazzi and colleagues. A separate 2026 prospective observational study compared perioperative neuron-specific enolase, adiponectin, and visinin-like protein-1 in adults receiving general or spinal anesthesia; its snippet reports that adiponectin declined perioperatively, possibly reflecting metabolic and inflammatory responses to surgical stress. A systematic review and meta-analysis of systemic adiponectin in colorectal cancer and adenoma was undertaken because prior reports were conflicting. The supplied material does not provide results from these investigations.
Prognostic Associations Can Conflict
Evidence on the prognostic value of circulating adiponectin is not uniformly consistent: sources describing a 2019 systematic review and meta-analysis say studies in patients with heart failure have reported conflicting findings. The meta-analysis set out to assess whether elevated circulating adiponectin was associated with adverse outcomes in that population. The supplied snippets do not report its pooled estimates or conclusions, and heart-failure evidence alone does not establish whether adiponectin predicts outcomes after cancer surgery.
Comparisons Across Procedures and Anesthesia
A study in Shiraz planned to measure adiponectin, leptin, and the adiponectin-to-leptin ratio in obese patients before and seven months after sleeve gastrectomy, Roux-en-Y gastric bypass, and single-anastomosis sleeve ileal procedures. Its stated aim was to compare changes and assess which bariatric procedure was most effective; the supplied snippet gives no comparative results. A separate prospective observational study planned to compare adiponectin and two other biomarkers in adults undergoing elective surgery with general versus spinal anesthesia. These study aims provide comparisons across procedures and anesthesia approaches, but the supplied material does not establish which approach produces better outcomes.
Implications for Patient Care and Future Research
This study provides valuable insights into the role of adiponectin in surgical recovery, suggesting that preoperative levels may serve as a predictive marker for postoperative complications in cancer patients. While the study involved a small number of patients, the findings highlight the potential for using adiponectin levels to identify individuals at higher risk and tailor their care accordingly.
Postoperative Adiponectin as a Prognostic Question
A prospective cohort study titled “Dynamic alterations in plasma adiponectin levels after surgery as a prognostic factor for gastric cancer” was listed as published on October 17, 2025. Its title frames postoperative changes in plasma adiponectin as a possible prognostic factor in gastric cancer. The supplied source provides no cohort details, results, or effect estimates, so it cannot establish whether these changes predict prognosis.
Adiponectin and Postoperative Inflammation
A study listed on August 26, 2026, was designed to investigate whether perioperative adiponectin, interleukin-6, and standard inflammatory blood biomarkers predict postoperative systemic inflammatory response syndrome and complications after colorectal cancer surgery. Two trial-record sources describe research in major abdominal or colorectal surgery based on the hypothesis that lower blood adiponectin is associated with a higher systemic inflammatory response. They state that the research aims to relate perioperative adiponectin levels to clinical signs and blood markers of systemic inflammation. These sources describe study aims and hypotheses, not confirmed findings.
The connection between adiponectin and oxidative stress also warrants further investigation. Understanding how these factors interact could lead to new strategies for minimizing surgical complications and improving patient outcomes. The scientists observed that the perioperative changes of serum concentration of APN were inversely related to changes of red cells' ROS and lypoperoxidation obtained in the same patient at different time points.
Future research should focus on larger studies to confirm these findings and explore the underlying mechanisms. Ultimately, this could lead to more personalized and effective approaches to surgical care for cancer patients.